Leukotriene B4 receptor 1 (BLT1), a high-affinity G protein-coupled receptor (GPCR) for leukotriene B4 (LTB4), plays important roles in inflammatory and immune reactions. Although the LTB4–BLT1 axis is known to promote inflammation, the binding proteins that modulate LTB4–BLT1 signaling have not been identified. Recently, we discovered that receptor for advanced glycation end products (RAGE) interacts with BLT1 and modulates LTB4–BLT1 signaling. We propose RAGE as a new class of GPCR modulator and a new target of future GPCR studies.
Get full access to this article
View all access options for this article.
References
1.
AchouitiA., van der MeerA.J., FlorquinS., YangH., TraceyK.J., van't VeerC., et al. (2013). High-mobility group box 1 and the receptor for advanced glycation end products contribute to lung injury during Staphylococcus aureus pneumonia. Crit Care, 17, R296.
2.
AkiravE.M., HenegariuO., Preston-HurlburtP., SchmidtA.M., ClynesR., and HeroldK.C. (2014). The receptor for advanced glycation end products (RAGE) affects T cell differentiation in OVA induced asthma. PLoS One, 9, e95678.
3.
BackM., BuD.X., BranstromR., SheikineY., YanZ.Q., and HanssonG.K. (2005). Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A, 102, 17501–17506.
4.
BlahoV.A., and HlaT. (2014). An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res, 55, 1596–1608.
5.
CarterA.B., and HunninghakeG.W. (2000). A constitutive active MEK→ERK pathway negatively regulates NF-kappa B-dependent gene expression by modulating TATA-binding protein phosphorylation. J Biol Chem, 275, 27858–27864.
6.
ChiangN., DalliJ., ColasR.A., and SerhanC.N. (2015). Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J Exp Med, 212, 1203–1217.
7.
DevchandP.R., AritaM., HongS., BannenbergG., MoussignacR.L., GronertK., et al. (2003). Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J, 17, 652–659.
8.
ForbesJ.M., YeeL.T., ThallasV., LassilaM., CandidoR., Jandeleit-DahmK.A., et al. (2004). Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes, 53, 1813–1823.
9.
HaribabuB., VergheseM.W., SteeberD.A., SellarsD.D., BockC.B., and SnydermanR. (2000). Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med, 192, 433–438.
10.
HellerE.A., LiuE., TagerA.M., SinhaS., RobertsJ.D., KoehnS.L., et al. (2005). Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation, 112, 578–586.
11.
HlaT., VenkataramanK., and MichaudJ. (2008). The vascular S1P gradient-cellular sources and biological significance. Biochim Biophys Acta, 1781, 477–482.
12.
IchikiT., KogaT., OkunoT., SaekiK., YamamotoY., YamamotoH., et al. (2016). Modulation of leukotriene B4 receptor 1 signaling by receptor for advanced glycation end products (RAGE). FASEB J, 30, 1811–1822.
13.
IizukaR., YoshidaT., IshiiN., ZakoT., TakahashiK., MakiK., et al. (2005). Characterization of archaeal group II chaperonin-ADP-metal fluoride complexes: implications that group II chaperonins operate as a “two-stroke engine.”. J Biol Chem, 280, 40375–40383.
14.
IizukaY., OkunoT., SaekiK., UozakiH., OkadaS., MisakaT., et al. (2010). Protective role of the leukotriene B4 receptor BLT2 in murine inflammatory colitis. FASEB J, 24, 4678–4690.
15.
IshiiY., SaekiK., LiuM., SasakiF., KogaT., KitajimaK., et al. (2016). Leukotriene B4 receptor type 2 (BLT2) enhances skin barrier function by regulating tight junction proteins. FASEB J, 30, 933–947.
16.
KimN.D., ChouR.C., SeungE., TagerA.M., and LusterA.D. (2006). A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J Exp Med, 203, 829–835.
17.
KrishnamoorthyS., RecchiutiA., ChiangN., YacoubianS., LeeC.H., YangR., et al. (2010). Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A, 107, 1660–1665.
18.
LammermannT., AfonsoP.V., AngermannB.R., WangJ.M., KastenmullerW., ParentC.A., et al. (2013). Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature, 498, 371–375.
19.
LiuM., SaekiK., MatsunobuT., OkunoT., KogaT., SugimotoY., et al. (2014). 12-Hydroxyheptadecatrienoic acid promotes epidermal wound healing by accelerating keratinocyte migration via the BLT2 receptor. J Exp Med, 211, 1063–1078.
20.
NeeperM., SchmidtA.M., BrettJ., YanS.D., WangF., PanY.C., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem, 267, 14998–15004.
21.
OkamotoF., SaekiK., SumimotoH., YamasakiS., and YokomizoT. (2010). Leukotriene B4 augments and restores Fc gammaRs-dependent phagocytosis in macrophages. J Biol Chem, 285, 41113–41121.
22.
OkunoT., IizukaY., OkazakiH., YokomizoT., TaguchiR., and ShimizuT. (2008). 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med, 205, 759–766.
23.
PatnodeM.L., BandoJ.K., KrummelM.F., LocksleyR.M., and RosenS.D. (2014). Leukotriene B4 amplifies eosinophil accumulation in response to nematodes. J Exp Med, 211, 1281–1288.
24.
RyckmanC., VandalK., RouleauP., TalbotM., and TessierP.A. (2003). Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol, 170, 3233–3242.
25.
SakaguchiM., MurataH., AoyamaY., HibinoT., PutrantoE.W., RumaI.M., et al. (2014). DNAX-activating protein 10 (DAP10) membrane adaptor associates with receptor for advanced glycation end products (RAGE) and modulates the RAGE-triggered signaling pathway in human keratinocytes. J Biol Chem, 289, 23389–23402.
26.
SakaguchiM., MurataH., YamamotoK., OnoT., SakaguchiY., MotoyamaA., et al. (2011). TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding. PLoS One, 6, e23132.
27.
SamuelssonB. (1983). Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science, 220, 568–575.
28.
SchiopuA., and CotoiO.S. (2013). S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease. Mediators Inflamm 2013,828354.
29.
SlowikA., MerresJ., ElfgenA., JansenS., MohrF., WruckC.J., et al. (2012). Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE)—and amyloid beta 1–42-induced signal transduction in glial cells. Mol Neurodegener 7,55.
30.
SoaresE.M., MasonK.L., RogersL.M., SerezaniC.H., FaccioliL.H., and AronoffD.M. (2013). Leukotriene B4 enhances innate immune defense against the puerperal sepsis agent Streptococcus pyogenes. J Immunol, 190, 1614–1622.
31.
Soro-PaavonenA., WatsonA.M., LiJ., PaavonenK., KoitkaA., CalkinA.C., et al. (2008). Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes, 57, 2461–2469.
32.
SubbaraoK., JalaV.R., MathisS., SuttlesJ., ZachariasW., AhamedJ., et al. (2004). Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol, 24, 369–375.
33.
TagerA.M., DufourJ.H., GoodarziK., BercuryS.D., von AndrianU.H., and LusterA.D. (2000). BLTR mediates leukotriene B(4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J Exp Med, 192, 439–446.
34.
TanakaN., YonekuraH., YamagishiS., FujimoriH., YamamotoY., and YamamotoH. (2000). The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem, 275, 25781–25790.
35.
TerawakiK., YokomizoT., NagaseT., TodaA., TaniguchiM., HashizumeK., et al. (2005). Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J Immunol, 175, 4217–4225.
36.
TodaA., TerawakiK., YamazakiS., SaekiK., ShimizuT., and YokomizoT. (2010). Attenuated Th1 induction by dendritic cells from mice deficient in the leukotriene B4 receptor 1. Biochimie, 92, 682–691.
37.
UenoH., KoyamaH., ShojiT., MondenM., FukumotoS., TanakaS., et al. (2010). Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apoE-deficient mouse. Atherosclerosis, 211, 431–436.
38.
VincentA.M., PerroneL., SullivanK.A., BackusC., SastryA.M., LastoskieC., et al. (2007). Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology, 148, 548–558.
39.
YamamotoY., and YamamotoH. (2012). Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications. J Diabetes Investig, 3, 107–114.
40.
YamamotoY., and YamamotoH. (2013). RAGE-mediated inflammation, type 2 diabetes, and diabetic vascular complication. Front Endocrinol 4,105.
41.
YaoD., and BrownleeM. (2010). Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes, 59, 249–255.
42.
YehP.Y., YehK.H., ChuangS.E., SongY.C., and ChengA.L. (2004). Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-kappaB activation by protein phosphatase 4-mediated NF-kappaB p65 Thr dephosphorylation. J Biol Chem, 279, 26143–26148.
43.
YokomizoT., IzumiT., ChangK., TakuwaY., and ShimizuT. (1997). A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature, 387, 620–624.
44.
YokomizoT., KatoK., TerawakiK., IzumiT., and ShimizuT. (2000a) A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med, 192, 421–432.
45.
YokomizoT., MasudaK., KatoK., TodaA., IzumiT., and ShimizuT. (2000b) Leukotriene B4 receptor. Cloning and intracellular signaling. Am J Respir Crit Care Med, 161, S51–S55.
46.
YungY.C., StoddardN.C., and ChunJ. (2014). LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res, 55, 1192–1214.
